The majority of advanced or metastatic breast cancer (ABC) patients are diagnosed with HR+, HER2− disease [1,2], and the introduction of CDK4/6 inhibitors in combination with endocrine therapies has significantly improved patient outcomes in this setting [3,4,38,39,40]. This evidence concerns the gene HR and aneurysmal bone cyst.